Fibrates, glitazones, and peroxisome ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
Titre :
Fibrates, glitazones, and peroxisome proliferator-activated receptors.
Auteur(s) :
Lalloyer, Fanny [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Staels, Bart [Auteur correspondant]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Staels, Bart [Auteur correspondant]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Titre de la revue :
Arteriosclerosis, Thrombosis, and Vascular Biology
Pagination :
894-9
Éditeur :
American Heart Association
Date de publication :
2010-05
ISSN :
1079-5642
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire
Résumé en anglais : [en]
Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of ...
Lire la suite >Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.Lire moins >
Lire la suite >Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Source :
Fichiers
- https://www.hal.inserm.fr/inserm-00475566/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-00475566/file/LalloyerStaels_HistoryPPARs.pdf
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-00475566/document
- Accès libre
- Accéder au document
- https://www.hal.inserm.fr/inserm-00475566/document
- Accès libre
- Accéder au document
- inserm-00475566_edited.pdf
- Accès libre
- Accéder au document
- LalloyerStaels_HistoryPPARs.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- inserm-00475566_edited.pdf
- Accès libre
- Accéder au document
- LalloyerStaels_HistoryPPARs.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- inserm-00475566_edited.pdf
- Accès libre
- Accéder au document
- LalloyerStaels_HistoryPPARs.pdf
- Accès libre
- Accéder au document